HOXA9 and acute myeloid leukemia: A survival analyses of both groups using Kaplan–Meier survival curves and the log-rank test confirmed that HOXA9 can be used as a marker of poor prognosis in AML (p < 0.001, Hazard Ratio 0.29 for low expression) (Fig. 2b) regardless of age (Fig. S3).